Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for influenza
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Risk for Subdeltoid Bursitis After Influenza Vaccination: A Population-Based Cohort Study. Subdeltoid bursitis has been reported as an adverse event after intramuscular vaccination in the deltoid muscle. Most published case reports involved influenza vaccine.To estimate the risk for subdeltoid bursitis after influenza vaccination.Retrospective cohort study.The Vaccine Safety Datalink, which contains health encounter data for 10.2 million members of 7 U.S. health care organizations.Persons who (...) received an inactivated influenza vaccine during the 2016-2017 influenza season.Potential incident cases were identified by searching administrative data for persons with a shoulder bursitis diagnostic code within 180 days after receiving an injectable influenza vaccine in the same arm. The date of reported bursitis symptom onset was abstracted from the medical record. A self-controlled risk interval analysis was used to calculate the incidence rate ratio of bursitis in a risk interval of 0 to 2 days
Historical Insights on Coronavirus Disease 2019 (COVID-19), the 1918 Influenza Pandemic, and Racial Disparities: Illuminating a Path Forward. The coronavirus disease 2019 (COVID-19) pandemic is exacting a disproportionate toll on ethnic minority communities and magnifying existing disparities in health care access and treatment. To understand this crisis, physicians and public health researchers have searched history for insights, especially from a great outbreak approximately a century ago (...) : the 1918 influenza pandemic. However, of the accounts examining the 1918 influenza pandemic and COVID-19, only a notable few discuss race. Yet, a rich, broader scholarship on race and epidemic disease as a "sampling device for social analysis" exists. This commentary examines the historical arc of the 1918 influenza pandemic, focusing on black Americans and showing the complex and sometimes surprising ways it operated, triggering particular responses both within a minority community and in wider racial
vaccine (surface antigen, inactivated, adjuvanted)) An overview of Fluad Tetra and why it is authorised in the EU What is Fluad Tetra and what is it used for? Fluad Tetra is a vaccine used to protect people aged from 65 years against influenza (flu). Flu is caused mainly by two types of influenza virus, known as influenza A and B. Each of these circulate as different strains, which change over time. Fluad Tetra will contain proteins from four different inactivated influenza A and B virus strains (two (...) strains of type A influenza virus of the subtypes H1N1 and H3N2 and two type B strains). They are chosen according to the official recommendation for the annual flu season. The vaccine also contains an adjuvant, which helps to improve the vaccine's effectiveness. The viruses used for producing Fluad Tetra are grown in fertilized hens’ eggs. How is Fluad Tetra used? Fluad Tetra is available as an injection in a pre-filled syringe. The recommended dose is a single injection (of 0.5 ml) into a muscle
Influenza vaccine: ovalbumin content Influenza vaccine: ovalbumin content - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance and support Guidance Influenza vaccine: ovalbumin content Data on the ovalbumin content of the influenza vaccines for the 2020 to 2021 flu season. Published (...) 29 July 2016 Last updated 10 June 2020 — From: Documents Ref: PHE publications gateway number 2019056 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This table lists all of the ovalbumin content of the influenza vaccines that are marketed in the UK for the 2020 to 2021 flu vaccination season
Baloxavir marboxil (Xofluza) - influenza Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012
Do Corticosteroids Benefit Patients With Influenza Pneumonia? Do Corticosteroids Benefit Patients With Influenza Pneumonia? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page To read this article in full, please review your options for gaining access at the bottom of the page. Article in Press Do Corticosteroids Benefit Patients With Influenza Pneumonia? x Michael Gottlieb , MD (EBEM Commentator) , x Thomas Seagraves , MD (EBEM (...) Commentator) , x Stephen R. Gore , MD (EBEM Commentator) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: Publication History Published online: July 23, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Among patients with influenza pneumonia, corticosteroids are associated with increased mortality, longer length of stay in the ICU, and higher rates of secondary infection, although there are no data from
The Effect of Influenza Vaccination for the Elderly on Hospitalization and Mortality: An Observational Study With a Regression Discontinuity Design. Observational studies using traditional research designs suggest that influenza vaccination reduces hospitalizations and mortality among elderly persons. Accordingly, health authorities in some countries prioritize vaccination of this population. Nevertheless, questions remain about this policy's effectiveness given the potential for bias (...) and confounding in observational data.To determine the effectiveness of the influenza vaccine in reducing hospitalizations and mortality among elderly persons by using an observational research design that reduces the possibility of bias and confounding.A regression discontinuity design was applied to the sharp change in vaccination rate at age 65 years that resulted from an age-based vaccination policy in the United Kingdom. In this design, comparisons were limited to individuals who were near the age-65
Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial. FLU-v is a broad-spectrum influenza vaccine that induces antibodies and cell-mediated immunity.To compare the safety, immunogenicity, and exploratory efficacy of different formulations and dosing regimens of FLU-v versus placebo.Randomized, double-blind, placebo-controlled, single-center phase 2b clinical trial. (ClinicalTrials.gov: NCT02962908; EudraCT: 2015 (...) vaccine efficacy against influenza infection.Adjuvanted FLU-v is immunogenic and merits phase 3 development to explore efficacy.SEEK and the European Commission Directorate-General for Research and Innovation, European Member States within the UNISEC (Universal Influenza Vaccines Secured) project.
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Antivirals are infrequently prescribed in European primary care for influenza-like illness, mostly because of perceived ineffectiveness in real world primary care and because individuals who will especially benefit have not been identified in independent trials. We aimed to determine whether adding antiviral treatment to usual primary care for patients (...) with influenza-like illness reduces time to recovery overall and in key subgroups.We did an open-label, pragmatic, adaptive, randomised controlled trial of adding oseltamivir to usual care in patients aged 1 year and older presenting with influenza-like illness in primary care. The primary endpoint was time to recovery, defined as return to usual activities, with fever, headache, and muscle ache minor or absent. The trial was designed and powered to assess oseltamivir benefit overall and in 36 prespecified
Avian influenza: guidance for managing human cases Avian influenza: guidance for managing human cases - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Avian influenza: guidance for managing human cases Information to assist with the management of possible and confirmed human (...) cases of avian influenza. Published 12 February 2014 Last updated 13 January 2020 — From: Documents Ref: PHE publications gateway number: GW-1025 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format
Avian influenza A(H5N6): risk assessment Avian influenza A(H5N6): risk assessment - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Avian influenza A(H5N6): risk assessment The risk to UK residents travelling to China is very low. This update includes information and advice (...) for travellers and clinicians. Published 15 February 2016 Last updated 8 January 2020 — From: Documents Ref: GW-997 HTML Details This update includes: background information risk assessment advice for travellers advice for clinicians The risk to UK residents travelling to China is very low. Published 15 February 2016 Last updated 8 January 2020 8 January 2020 Updated 'Avian influenza A(H5N6): risk assessment.' 17 April 2018 Updated 'Avian influenza A(H5N6): risk assessment.' 21 April 2017 Updated version
respiratory syndrome[MeSH Terms] #8 flu OR influenza OR grippe OR SARS OR “severe acute respiratory syndrome”[Text Word] #9 #7 OR #8 #10 #3 AND #6 AND #9 2.3 Study selection and data extraction Two reviewers independently screened the articles based on the titles, abstracts and full texts. Then, two reviewers independently exacted the following data from included studies: first author, publication year, country, disease, details of study population and intervention, study design, sample size, settings (...) and fit loosely to the user's face. 5,6 Although surgical masks cannot prevent inhalation of small airborne particles, both of them can protect users from large droplets and sprays. , There are conflicting recommendations for severe acute respiratory syndrome (SARS) and pandemic influenza: the World Health Organization (WHO) recommends using masks in low‐risk situations and respirators in high‐risk situations, but the Centers for Disease Control and Prevention (CDC) recommends using respirators
pandemics “Swine Flu” (CDC) estimated that 150, 000 to 575,000 people died from (H1N1) pandemic virus infection in the first year of the outbreak. 80% of the virus-related deaths were estimated to occur in those < 65 years of age. In seasonal influenza epidemics, about 70% to 90% of deaths occur in people ≥65. by the WHO: However, typical seasonal influenza causes most of its deaths among the elderly while other severe cases occur most commonly in people with a variety of medical conditions. By contrast (...) COVID-19 deaths compared with 'Swine Flu' COVID-19 deaths compared with “Swine Flu” - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website COVID-19 deaths compared with “Swine Flu” April 9, 2020 The age affected structure doesn’t fit with pandemic theory Carl Heneghan, Tom Jefferson “It is a capital mistake to theorize before one has data. Insensibly one begins to twist facts to suit theories, instead
COVID-19: Surge Triage for Suspected Influenza-Like Illness COVID-19: SURGE TRIAGE FOR SUSPECTED INFLUENZA-LIKE ILLNESS A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated March 29, 2020, 2:00 pm All links rechecked March 28 unless otherwise noted. Key questions answered in this summary • What options are available to help hospitals manage triage of patients with suspected COVID-19 infection? • How should patients be directed through triage when
Invasive Nontypeable Haemophilus influenzae Infection Among Adults With HIV in Metropolitan Atlanta, Georgia, 2008-2018. Invasive nontypeable Haemophilus influenzae (NTHi) infection among adults is typically associated with bacteremic pneumonia. Nontypeable H influenzae is genetically diverse and clusters of infection are uncommon.To evaluate an increase in invasive NTHi infection from 2017-2018 among HIV-infected men who have sex with men in metropolitan Atlanta, Georgia.A population-based (...) isolates) carried IS1016 (an insertion sequence associated with H influenzae capsule genes). Persons with HIV were significantly more likely to have C1 or C2 invasive NTHi infection from 2017-2018 (28/31 [90%]) compared with from 2008-2016 among persons with HIV (10/24 [42%]; P < .001) and compared with from 2008-2018 among those without HIV (9/119 [8%]; P < .001). Among persons with C1 or C2 invasive NTHi infection who had HIV (n = 38) (median age, 34.5 years; 100% male; 100% black; 82% men who have
materials to provide key audiences with information on seasonal influenza and encourage vaccination and the adoption of good hygiene practices. The toolkit guidance also includes suggested tactics for getting the message across to different audiences. Moreover, a logo has been created (‘Against the flu’) which can be used in conjunction with national initiatives at various events. Types of materials Prototype materials contained in this toolkit provide a hierarchy of information ranging from the concise (...) t the flu’ c an be tr an s l at ed into local languages. Posters The poster presents basic facts on influenza and key preventive messages which can be read and understood quickly. More detailed content can be made available to target audiences via factsheets and brochures but can also appear on websites and in other materials. Factsheets The tw o-p ag e f actsheets (1 30 x 2 50 mm) pr o v ide key information presented very synthetically. A lthough they c ont ain mor e t e xt th an the po s t er